S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?

TScan Therapeutics (TCRX) News Today

$6.45
-0.34 (-5.01%)
(As of 02/27/2024 ET)
SourceHeadline
markets.businessinsider.com logoStrong Buy Rating for TScan Therapeutics Backed by Positive Phase 1 Trial Data and Promising Treatment Efficacy
markets.businessinsider.com - February 27 at 11:17 PM
markets.businessinsider.com logoBuy Rating Affirmed for TScan Therapeutics Following Promising TCR-T Therapy Trial Outcomes
markets.businessinsider.com - February 27 at 11:17 PM
MarketBeat logoWedbush Reaffirms "Outperform" Rating for TScan Therapeutics (NASDAQ:TCRX)
americanbankingnews.com - February 27 at 4:28 AM
globenewswire.com logoTScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
globenewswire.com - February 26 at 7:00 AM
markets.businessinsider.com logoBuy Rating for TScan Therapeutics Supported by Iovance’s FDA Approval and Promising TIL Therapy Benchmark
markets.businessinsider.com - February 21 at 4:22 PM
finance.yahoo.com logoTScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar?
finance.yahoo.com - February 19 at 8:55 AM
baystreet.ca logoGlobal Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates
baystreet.ca - February 14 at 11:15 PM
finance.yahoo.com logoTScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
finance.yahoo.com - February 14 at 8:13 AM
globenewswire.com logoTScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
globenewswire.com - February 14 at 7:00 AM
finance.yahoo.com logoTScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
finance.yahoo.com - February 6 at 10:32 AM
marketbeat.com logoTScan Therapeutics' (TCRX) "Outperform" Rating Reaffirmed at Wedbush
marketbeat.com - February 1 at 10:42 AM
msn.com logoTScan Therapeutics Welcomes Jason Amello as New CFO
msn.com - January 30 at 4:51 PM
markets.businessinsider.com logoTScan Appoints Jason Amello As CFO
markets.businessinsider.com - January 29 at 9:00 AM
msn.com logoTScan Therapeutics appoints CFO
msn.com - January 29 at 9:00 AM
finance.yahoo.com logoTScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
finance.yahoo.com - January 29 at 9:00 AM
marketbeat.com logoTScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Down 14.6% in January
marketbeat.com - January 28 at 7:35 PM
finance.yahoo.com logoTScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
finance.yahoo.com - January 18 at 7:25 AM
markets.businessinsider.com logoStrong Buy Rating for TScan Therapeutics Amid Progressive Clinical Advancements
markets.businessinsider.com - January 5 at 8:11 PM
seekingalpha.com logoTScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value
seekingalpha.com - December 27 at 8:23 PM
finance.yahoo.com logoTimothy Barberich Bought 41% More Shares In TScan Therapeutics
finance.yahoo.com - December 23 at 7:51 AM
marketbeat.com logoTimothy J. Barberich Purchases 28,830 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock
marketbeat.com - December 21 at 6:48 PM
marketbeat.com logoInsider Buying: TScan Therapeutics, Inc. (NASDAQ:TCRX) Director Acquires 5,000 Shares of Stock
marketbeat.com - December 18 at 7:23 PM
finance.yahoo.com logoTScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
finance.yahoo.com - December 9 at 1:02 PM
finance.yahoo.com logoTScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
finance.yahoo.com - December 7 at 7:58 AM
finance.yahoo.com logoRecent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's Why
finance.yahoo.com - December 6 at 2:52 PM
finance.yahoo.com logoTScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition
finance.yahoo.com - December 4 at 8:32 PM
finance.yahoo.com logoDoes TScan Therapeutics, Inc. (TCRX) Have the Potential to Rally 62.33% as Wall Street Analysts Expect?
finance.yahoo.com - December 1 at 2:03 PM
finance.yahoo.com logoTScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years
finance.yahoo.com - November 30 at 9:13 AM
markets.businessinsider.com logoBuy Rating Affirmed: TScan Therapeutics’ Innovative TCR-T Cell Therapies Poised to Transform Cancer Treatment
markets.businessinsider.com - November 28 at 6:21 PM
finance.yahoo.com logoWith TScan Therapeutics Up 12%, Insider Buyers Count Their Returns
finance.yahoo.com - November 28 at 8:20 AM
finance.yahoo.com logoTScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock: Should You Buy?
finance.yahoo.com - November 27 at 4:19 PM
finance.yahoo.com logoTScan Therapeutics, Inc. (TCRX) Is a Great Choice for 'Trend' Investors, Here's Why
finance.yahoo.com - November 20 at 12:47 PM
finance.yahoo.com logoWhat Makes TScan Therapeutics, Inc. (TCRX) a New Buy Stock
finance.yahoo.com - November 15 at 6:54 PM
msn.com logoWall Street Analysts Predict a 125% Upside in TScan Therapeutics, Inc. (TCRX): Here's What You Should Know
msn.com - November 15 at 1:38 PM
finance.yahoo.com logoWall Street Analysts Predict a 125% Upside in TScan Therapeutics, Inc. (TCRX): Here's What You Should Know
finance.yahoo.com - November 15 at 1:38 PM
markets.businessinsider.com logoTD Cowen Keeps Their Buy Rating on TScan Therapeutics (TCRX)
markets.businessinsider.com - November 10 at 3:18 PM
benzinga.com logoRecap: TScan Therapeutics Q3 Earnings
benzinga.com - November 9 at 1:37 PM
finance.yahoo.com logoTScan Therapeutics Inc (TCRX) Reports Q3 2023 Financial Results and Corporate Updates
finance.yahoo.com - November 9 at 1:37 PM
finance.yahoo.com logoTScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 8:37 AM
finance.yahoo.com logoTScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting
finance.yahoo.com - November 6 at 9:35 AM
finance.yahoo.com logoTScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition
finance.yahoo.com - November 2 at 10:12 AM
finance.yahoo.com logoWith 51% ownership in TScan Therapeutics, Inc. (NASDAQ:TCRX), hedge funds investors have a lot riding on the business
finance.yahoo.com - October 18 at 10:56 AM
finance.yahoo.com logoTScan Therapeutics, Inc. (TCRX) Upgraded to Strong Buy: Here's Why
finance.yahoo.com - October 12 at 6:14 PM
seekingalpha.com logoBTWN, OMAB and PAC among mid-day movers
seekingalpha.com - October 5 at 1:26 PM
finance.yahoo.com logoTScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting
finance.yahoo.com - September 27 at 9:58 AM
finance.yahoo.com logoSensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors
finance.yahoo.com - September 12 at 9:19 AM
finance.yahoo.com logoTScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
finance.yahoo.com - August 29 at 8:16 AM
finance.yahoo.com logoTScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should Know
finance.yahoo.com - August 16 at 6:02 PM
markets.businessinsider.com logoBarclays Remains a Buy on TScan Therapeutics (TCRX)
markets.businessinsider.com - August 11 at 6:10 AM
finance.yahoo.com logoTScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 10 at 9:56 AM
Get TScan Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter.



TCRX Media Mentions By Week

TCRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TCRX
News Sentiment

0.40

0.51

Average
Medical
News Sentiment

TCRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TCRX Articles
This Week

7

1

TCRX Articles
Average Week

Get TScan Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:TCRX) was last updated on 2/28/2024 by MarketBeat.com Staff